Arcus Biosciences (RCUS) Receivables - Other (2017 - 2026)

Arcus Biosciences' Receivables - Other history runs 10 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Receivables - Other fell 73.33% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (down 73.33% YoY), while the FY2025 annual figure was $11.0 million, down 45.0% from the prior year.
• Receivables - Other was $4.0 million for Q1 2026 at Arcus Biosciences, down from $11.0 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $52.0 million in Q3 2023 to a low of $3.0 million in Q2 2024.
• Historically, Receivables - Other has averaged $17.6 million across 5 years, with a median of $14.0 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Receivables - Other soared 795.78% in 2022, then plunged 91.18% in 2024.
• A 5-year view of Receivables - Other shows it stood at $14.0 million in 2022, then soared by 171.16% to $38.0 million in 2023, then tumbled by 47.37% to $20.0 million in 2024, then tumbled by 45.0% to $11.0 million in 2025, then sank by 63.64% to $4.0 million in 2026.
• The last three Receivables - Other figures came in at $4.0 million (Q1 2026), $11.0 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.